Abstracts: Multiple Sclerosis and Related Disorders
Multiple Sclerosis and Related Disorders
- A case-control metabolomic analysis of MS and CIS cases
- An Assay of MX1 Gene Expression, a Molecular Biomarker of Beta-Interferon Neutralising Antibodies
- An Australian case of natalizumab-associated progressive multifocal leukoencephalopathy
- Anti-CV2 antibody syndrome: A case of paraneoplastic cerebellar degeneration, myelitis and peripheral neuropathy
- Anti-HHV-6 & EBV IgG and clinical outcomes in multiple sclerosis
- Correlation of the Multiple Sclerosis International Quality of Life questionnaire (MusiQoL) and the 36-item Short Form questionnaire (SF-36) with changes in Expanded Disability Status Score (EDSS) in patients with multiple sclerosis
- Cortical Atrophy Underlies Disability Development In Multiple Sclerosis
- Electrically evoked VOR, three-dimensional head impulse testing and ocular vestibular evoked myogenic potentials (OVEMP) in multiple sclerosis patients with internuclear ophthalmoplegia
- Long-term safety and efficacy of cladribine tablets therapy in relapsing and early forms of multiple sclerosis: report of a clinical development plan and prospective registry
- Multiple sclerosis and headache - a case-control study in Queensland
- Ophthalmoplegic migraine: A rapid clinical and radiological response to intravenous corticosteroids
- Recurrent CNS inflammation with suspension of Natalizumab dosing during pregnancy
- Safety profile of cladribine tablets in two consecutive treatment periods in relapsing remitting MS: results from the phase III, 96 week CLARITY study
- Smoking increases the risk of multiple sclerosis – a case-control study in Queensland and a meta-analysis
- Sustained disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets: results from the phase III, 96-week CLARITY study
- The clinical, radiological and histopathological phenotype of a novel neuroinflammatory disorder
- The Effect of Geography, Gender, Year of Birth and MS phenotype on the Age of Onset of Multiple Sclerosis
- The vitamin D pathway and Multiple Sclerosis
- Trial-Defined Disease Progression in Multiple Sclerosis is a Sub-optimal Measure of Permanent Disability Progression
- Variable Course and Treatment if Idiopathic Hypertrophic Pachymeningitis: 2 case reports
20 abstracts